This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutPresentationsCategories of AnticoagulantsSupport & ResourcesSupport & ResourcesPatient ResourcesUsing Fragmin Needle TrapVideosMaterials

Prescribing information for Fragmin® (dalteparin sodium) can be found here. Adverse event reporting can be found at the bottom of the page.

Fragmin (dalteparin sodium)​Choose FragminFragmin is a low molecular heparin with a number of indications which include extended treatment of symptomatic venous thromboembolism (VTE) and prevention of its recurrence in patients with solid tumours.2-7

There is a wealth of experience with Fragmin and a broad range of indications for your patients

Established clinical experience:
  • ​​​​​​​To date more than 85 million Fragmin syringes, vials and ampoules have been used in the UK1
Broad range of clinical indications2-7 Adults
  • Treatment of VTE presenting clinically as deep vein thrombrosis (DVT), pulmonary embolism (PE) or both
  • Extended treatment of symptomatic VTE and prevention of its recurrence in patients with solid tumours
  • Peri- and post-operative surgical thromboprophylaxis
  • Thromboprophylaxis in patients bedridden due to a medical condition*
  • Unstable angina and non-Q wave MI, administered concurrently with aspirin
  • Prevention of clotting in the extracorporeal circulation during haemodialysis or haemofiltration†
Paediatrics
  • Treatment of symptomatic VTE in paediatric patients 1 month of age and older 

*Including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for VTE such as age over 75 years, obesity, cancer or previous history of VTE.

†In patients with chronic renal insufficiency or acute renal failure.

MI, Myocardial Infarction; NYHA, New York Heart Association

 

Simple adult dosing regimen:

Once or twice daily dosing for adults using colour-coded syringes and other presentations2-7

 Using Fragmin Needle-Trap

Click below to learn how to use a Fragmin Needle-Trap

 Learn more Loading Patient Resources

Discover our range of patient resources

 Discover more Loading Fragmin Presentations Discover more Loading Categories of Anticoagulants Find out more LoadingReferencesData on File (IMS Data).Fragmin SmPC [Surgical Thromboprophylaxis (2,500 IU and 5,000 IU syringes)]. Available at: https://www.medicines.org.uk/emc/product/4246 and https://www.medicines.org.uk/emc/product/4247Fragmin SmPC [Medical Thromboprophylaxis (5,000 IU syringes)]. Available at: https://www.medicines.org.uk/emc/product/4247Fragmin SmPC [Treatment of VTE (7,500-18,000 IU syringes, 10,000 IU/1 ml ampoules, 100,000 IU/4 ml Multidose Vial)]. Available at: https://www.medicines.org.uk/emc/search?q=fragminFragmin SmPC [Unstable Angina (Graduated syringe 10,000 IU/ml solution for injection, 10,000 IU/1 ml ampoule, 7,500 IU)]. Available at: https://www.medicines.org.uk/emc/search?q=fragminFragmin SmPC [Haemodialysis/Haemofiltration (10,000 IU/1 ml & 10,000 IU/4 ml ampoules)]. Available at: https://www.medicines.org.uk/emc/product/4251 and https://www.medicines.org.uk/emc/product/4244Fragmin SmPC [Extended Treatment in Oncology (5,000-18,000 IU syringes)]. Available at: https://www.medicines.org.uk/emc/search?q=fragmin
PP-FRA-GBR-0346. August 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​